Skip to main content

Market Overview

Unity Biotech Craters After Lead Drug Flunks Midstage Osteoarthritis Study

Share:
Unity Biotech Craters After Lead Drug Flunks Midstage Osteoarthritis Study

Shares of Unity Biotechnology Inc (NASDAQ: UBX), which went public in mid-2018, were moving notably lower Monday following an adverse clinical readout.

What Happened: San Francisco, California-based Unity said the 12-week results from the Phase 2 study of its lead asset UBX0101 showed that the trial did not meet the primary endpoint.

The study looked at the p53/MDM2 interaction inhibitor in patients with moderate-to-severe painful osteoarthritis of the knee.

"There was no statistically significant difference between any arm of UBX0101 and placebo at the 12-week endpoint for change from baseline in WOMAC-A, an established measurement of pain in OA," Unity said in a statement.

UBX0101 is the most advanced investigational therapy in Unity's pipeline.

What's Next: Given the results, the company said it does not expect to advance UBX0101 into pivotal studies and will instead narrow its near-term focus to its ongoing ophthalmologic and neurologic disease programs.

Unity also said it expects to complete collection of the 24-week data from the Phase 2 study, as well as that from the ongoing Phase 1b high-dose, repeat-dose study in the second half of 2020. Data from the Phase 2 and Phase 1b studies will be presented at a future medical meeting, it added.

UBX Price Action:  At last check, Unity shares were plunging 65.41% to $4.30. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

 

Related Articles (UBX)

View Comments and Join the Discussion!

Posted-In: Biotech News Top Stories Movers Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com